Albemarle Corporation First Quarter 2020 Earnings

Conference Call/Webcast Thursday, May 7, 2020 9:00am ET



Forward-Looking Statements

Some of the information presented in this presentation, the conference call and discussions that follow, including, without limitation, statements with respect to product development, market trends, price, expected growth and earnings, demand for our products, capital projects, tax rates, stock repurchases, dividends, cash flow generation, economic trends, outlook and all other information relating to matters that are not historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the views expressed.

Factors that could cause actual results to differ materially from the outlook expressed or implied in any forward-looking statement include, without limitation: changes in economic and business conditions; changes in financial and operating performance of our major customers and industries and markets served by us; the timing of orders received from customers; the gain or loss of significant customers; competition from other manufacturers; changes in the demand for our products or the end-user markets in which our products are sold; limitations or prohibitions on the manufacture and sale of our products; availability of raw materials; increases in the cost of raw materials and energy, and our ability to pass through such increases to our customers; changes in our markets in general; fluctuations in foreign currencies; changes in laws and government regulation impacting our operations or our products; the occurrence of regulatory proceedings, claims or litigation; the occurrence of cyber-security breaches, terrorist attacks, industrial accidents, natural disasters or climate change; hazards associated with chemicals manufacturing; the inability to maintain current levels of product or premises liability insurance or the denial of such coverage; political unrest affecting the global economy, including adverse effects from terrorism or hostilities; political instability affecting our manufacturing operations or joint ventures; changes in accounting standards; the inability to achieve results from our global manufacturing cost reduction initiatives as well as our ongoing continuous improvement and rationalization programs; changes in the jurisdictional mix of our earnings and changes in tax laws and rates; changes in monetary policies, inflation or interest rates that may impact our ability to raise capital or increase our cost of funds, impact the performance of our pension fund investments and increase our pension expense and funding obligations; volatility and uncertainties in the debt and equity markets; technology or intellectual property infringement, including cyber-security breaches, and other innovation risks; decisions we may make in the future; the ability to successfully execute, operate and integrate acquisitions and divestitures; uncertainties as to the duration and impact of the coronavirus (COVID-19) pandemic; and the other factors detailed from time to time in the reports we file with the SEC, including those described under "Risk Factors" in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this presentation. We assume no obligation to provide any revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

ALBEMARLE®

Non-GAAP Financial Measures

It should be noted that Adjusted net income attributable to Albemarle Corporation ("Adjusted earnings"), Adjusted diluted earnings per share attributable to Albemarle Corporation, Adjusted effective income tax rates, segment operating profit, segment income, pro-forma net sales, net sales excluding the impact of foreign exchange translation ("ex FX"), EBITDA, Adj. EBITDA, Adj. EBITDA by operating segment, EBITDA margin, Adj. EBITDA margin, Adj. EBITDA margin, Adj. EBITDA margin, Adj. EBITDA margin excluding the impact of foreign exchange translation ("ex FX"), Adj. EBITDA excluding the impact of foreign exchange translation ("ex FX"), net debt to Adj. EBITDA, gross debt to Adj. EBITDA, free cash flow, and Adjusted free cash flow are financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States, or GAAP. These measures are presented here to provide additional useful measurements to review our operations, provide transparency to investors and enable period-to-period comparability of financial performance. The Company's chief operating decision maker uses these measures to assess the ongoing performance of the Company and its segments, as well as for business and enterprise planning purposes.

A description of these and other non-GAAP financial measures that we use to evaluate our operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, can be found in the Appendix to this presentation. The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable financial measures are uncertained to estimate significant non-recurring or unusual items without unreasonable effort. The amounts and timing of these items are uncertain and could be material to the Company's results calculated in accordance with GAAP.



Taking Action to Position Albemarle for the Present and the Future

ALBEMARLE®



COVID-19 RESPONSE Protect Employees, Customers, Suppliers and Communities

Communication

Albemarle Executive Leadership Team meeting multiple times per week:

- COVID-19 global cross-functional response team update and recommendations
- Employee health and safety status/actions
- Business, Supply Chain, Manufacturing and Operations status/actions
- Financial status/actions

Frequent communication with employees

- Weekly email from CEO
- Weekly update from each GBU
 president, virtual town halls
- Weekly status and protocol update on company intranet

Actions	Taken
/ 0010110	ianon

ACTIONS TAKEN	
Employees	S Business Partners
 Protocols to decrease risk for our team, partners and communities Travel restrictions, work-fromhome, adjusted shift schedules Health screening, social distancing at the worksite Return-to-work protocols 	 Frequent communications with customers to help us manage and meet their demand Plant entry protocol in place for safe and efficient deliveries
Manufacturing & Operations	© Communities
 Business continuity plans in place to serve our customers with minimal disruption Agile logistics team Ability to ship from multiple ports and freight lines Multi-source raw materials and supplies, where possible 	 To date Albemarle, the Albemarle Foundation, and our JBC JV have contributed ~\$1.2M to help those in need Donations of PPE globally Fighting hunger Relief for medical responders Research grants Improving access to learning

🛦 ALBEMARLE°

Adjusting Capital Allocation Priorities

Adapting to Current Environment

01	 Fund the Dividend 26th year of consecutive dividend increases Targeting long-term median specialty chemical payout ratio 	Committed to shareholder returns
02	 Maintain Financial Flexibility Maintain Investment Grade rating Long-term Net Debt to Adj. EBITDA Target: 2.0x - 2.5x 	Committed to investment grade credit rating
03	 Invest to Grow Profitably Strategically grow lithium capacity Accelerate productivity projects Build or buy conversion 	Delaying capital expenditures
04	 Growth via M&A and / or JVs Improved capital efficiency Low-cost resources and operations 	Disciplined approach to investment opportunities
05	 Repurchase Shares Return excess cash to shareholders Board authorization up to 7M additional shares 	Authorization remains in place; no near-term planned buybacks

ALBEMARLE®

Q1 2020 Financial Summary

(in millions, except per share amounts)	Q1 2020	Q1 2019	Variance
Net Sales	\$739	\$832	-11%
Net Income Attributable to Albemarle Corporation	\$107	\$134	-20%
Adjusted EBITDA	\$196	\$226	-13%
Diluted EPS	\$1.01	\$1.26	-20%
Non-operating Pension and OPEB items	(0.02)	(0.01)	
Non-recurring and Other Unusual Items	0.01	(0.02)	
Adjusted Diluted EPS	\$1.00	\$1.23	-19%
Adjusted EBITDA Margin	27%	27%	

ALBEMARLE°

Q1 2020 Adjusted EBITDA¹ Bridge



¹ Note: Bridge numbers may not reconcile due to rounding. ² Corporate and Other includes Fine Chemistry Services (FCS).

ALBEMARLE*

Proprietary Information of Albemarle Corporation

Strong Financial Position and Ample Liquidity (As of 3/31/20, \$M)



\$350

\$300

- \$553M cash and cash equivalents
- \$250M drawn on revolver
- Net debt to adjusted EBITDA is 2.7x
- Leverage (gross debt to EBITDA) is 3.2x versus current covenant of 4.0x
- Currently negotiating covenant waiver to ensure on-going financial flexibility
- Weighted average interest of 2.7%
- Working capital typically averages ~25% of net sales; extending vendor payment terms; drawing down inventories
- Divestures slowed due to COVID-19: opportunity for cash infusion
- Subsequent event in April, \$200M drawn on term Ioan

Committed to Maintaining Investment Grade Credit Rating



Accelerating 2020 Sustainable Cost Savings Initiative

- Executing on existing cost management project identified in 2019 totaling a \$100M+ run rate YE 2021
- Now expecting \$50-\$70M in year one; pulling forward \$10 to \$20 million additional savings

Factory Spend and Operational Efficiency Raw material yield and cost Energy and waste Supply Chain Logistics optimization Indirect spend outsourcing Facility reduction Sales & Administration and IBO 3rd-party consulting IT efficiencies investments and global systems

Three Buckets of Identified Cost Savings

Total Expected Cost Savings by Business Unit



Cost savings plan in place prior to COVID-19; accelerating pace of capture



Q2 2020 Outlook and Assumptions

	Q2 2020 Outlook
Net sales	\$700 - \$775 million
Adjusted EBITDA	\$140 - \$190 million

Lithium

- · Q2 2020 adjusted EBITDA expected to be down YoY, but up slightly sequentially
- Stable Q2 energy storage orders as cathode and battery producers fill order backlogs; weaker specialties and technical grade (TG) orders

Bromine Specialties

- Q2 2020 adjusted EBITDA expected to be down ~20% YoY
- Early indications that some customers may push orders from late Q2 into Q3

Catalysts

- Q2 2020 adjusted EBITDA could be down ~50% YoY
- Fluid catalytic cracking (FCC) impacted by full quarter of stay-at-home orders and reduced transportation fuel consumption; Expect minimal impact to Q2 order book for Clean Fuel Technologies (Hydroprocessing Catalysts or HPC)

ALBEMARLE®

Executing Our Downturn Playbook for Short-Term Cash Management

		Status
Variable Costs	 Aggressively pursue lower raw material pricing Continue travel restrictions Limit professional services Pursue economic incentives (e.g., stimulus plans/tax deferrals) Reduced metric-based incentives and annual bonus plan 	✓ Activated
Fixed Costs	 Strict limits on hiring, overtime, contractors Reduced capital expenditures C-Suite and Board compensation reductions 	✓ Activated
Production	Idle production sites as market demands dictateRestructure supply chain	✓ Activated, as needed
Working Capital	Reduce inventorySeek vendor payment extensionsAccelerate collection of receivables	✓ Activated

Short-term cash management actions save ~\$25-\$40M per quarter; FY 2020 capex spending down ~\$150M from plan

ALBEMARLE®

Status

Q1 2020 Overview: Lithium

Q1 2020 PERFORMANCE

(\$M)	Q1 2020	ΔQ1 2019
Net Sales	\$237	-19%
Net Sales ex FX ¹	\$240	-18%
Adj. EBITDA	\$79	-32%
Adj. EBITDA ex FX ¹	\$76	-35%
Adj. EBITDA Margin	33%	(640) bps
Adj. EBITDA Margin ex FX1	32%	(807) bps

HISTORICAL TREND (TTM)



Q1 Performance Drivers

- Net sales down 19% and adjusted EBITDA down 32%
 - Lower contract pricing (reflecting 2020 price adjustments) and reduced volume as customer took excess volume in Q4 2019
 - · Partially offset by cost savings initiatives and favorable customer/product mix

Outlook

- Energy storage/battery grade (BG): anticipating potential H2 2020 impact as battery
 and cathode producers complete backlog and begin to respond to OEM shutdowns
- Specialties and technical grade (TG): Q2 2020 impact due to customer closures and order cancellations in industrial production (polymer, glass, grease) related to COVID-19

Drivers/Sensitivities

- Energy storage (~60% of Li sales): Primary driver EV sales in Europe and China
 - Potentially 1 to 2 quarter lag behind EV production
- Specialties and TG (~40% of Li sales): Primary driver consumer spending and industrial production
 - Less than 1 quarter lag in the downturn, relatively quick rebound in the upturn

Note: Numbers may not reconcile due to rounding. ¹ Net of FX impacts.

Q1 2020 Overview: Bromine Specialties

Q1 2020 PERFORMANCE

(\$M)	Q1 2020	ΔQ1 2019
Net Sales	\$232	-7%
Net Sales ex FX ¹	\$230	-8%
Adj. EBITDA	\$83	6%
Adj. EBITDA ex FX ¹	\$84	7%
Adj. EBITDA Margin	36%	439 bps
Adj. EBITDA Margin ex FX ¹	36%	487 bps

HISTORICAL TREND (TTM)



Q1 Performance Drivers

- Net sales down 7% due primarily to logistics challenges that shifted some orders into Q2, partially offset by higher pricing
- Adjusted EBITDA up 6% due to cost saving initiatives and lower minority interest expense, which more than offset reduced net sales

Outlook

- Q2 2020 EBITDA anticipated to be down ~20% year-over-year
- Reduced demand driven by COVID-19 may begin to impact late Q2 2020 and continue into H2 2020

Drivers/Sensitivities

- GDP driven business electronics, automotive, construction, appliances
- Flame retardants (~ 50% of sales): Primary driver consumer spending / GDP
 - Driven in part by consumer markets
- Oilfield (< 20% of sales): Primary driver oil price
 - Deep water and off-shore drilling
- ~1 to 3 quarter lag in supply chain; typically rebounds quickly post-recession

Q1 2020 Overview: Catalysts

Q1 2020 PERFORMANCE

(\$M)	Q1 2020	ΔQ1 2019
Net Sales	\$207	-18%
Net Sales ex FX ¹	\$205	-18%
Adj. EBITDA	\$47	-21%
Adj. EBITDA ex FX ¹	\$49	-19%
Adj. EBITDA Margin	23%	(96) bps
Adj. EBITDA Margin ex FX1	24%	(3) bps

HISTORICAL TREND (TTM)



Q1 Performance Drivers

- Net sales down by 18% and adjusted EBITDA down by 21%
 - FCC volume was down from lower transportation fuel consumption as a result of stay-at-home orders and travel restrictions
 - HPC volume was down due to logistics disruptions related to COVID-19

Outlook

- FCC impacted by stay-at-home orders and travel restrictions; reduced transportation fuel consumption began in Q1 2020 in Asia and is expected to continue into Q2 in the rest of the world
- HPC Q2 order book largely secure; based on prior downturns expect H2 2020 orders to be pushed into 2021 as refineries push out turnarounds

Drivers/Sensitivities

- FCC: Primary drivers miles driven/transportation fuel consumption
 - Very little lag time with changes in fuel consumption
- HPC: Primary driver environmental sulfur regulations and customer turnarounds
 - 1 to 2 quarter lag into the downturn as refineries push out turnarounds, similar lag in the upturn
- Through cycle, both business are roughly the same size; HPC business is lumpy due to customer turnaround timing

Second Quarter 2020 Investor Relations Events

Date	Event – All Virtual
May 26	Non-Deal Roadshow
May 29	Bernstein Strategic Decisions Conference
June 1 – 4	Non-Deal Roadshow
June 9	Deutsche Bank Conference

Meredith Bandy

VP, Investor Relations & Sustainability meredith.bandy@albemarle.com +1 980.999.5168 Sharon McGee VP, Investor Relations sharon.mcgee@albemarle.com +1 980.299.5601 Mark de Boer Director, Sustainability mark.deboer@albemarle.com +31 20.634.7060





Non-GAAP Reconciliations



NON-GAAP MEASURE	DESCRIPTION
Adjusted Net Income	Net income attributable to Albemarle Corporation before non-recurring, other unusual and non-operating pension and OPEB.
Pro-forma Adjusted Net Income	Net income attributable to Albemarle Corporation before non-recurring, other unusual and non-operating pension and OPEB items, and the net impact of the divested business.
Adjusted Diluted EPS	Diluted EPS before non-recurring, other unusual and non-operating pension and OPEB.
Pro-forma Adjusted Diluted EPS	Diluted EPS before non-recurring, other unusual and non-operating pension and OPEB items, and the net impact of the divested business.
EBITDA	Net income attributable to Albemarle Corporation before interest and financing expenses, income taxes, and depreciation and amortization.
Adjusted EBITDA	EBITDA before non-recurring, other unusual and non-operating pension and OPEB.
Pro-forma Adjusted EBITDA	Adjusted EBITDA before the net impact of EBITDA of the divested business.
Pro-forma Net Sales	Net Sales before the impact of Net Sales from the divested business.
Adjusted Effective Income Tax Rate	Reported effective income tax rate before the tax impact of non-recurring, other unusual and non-operating pension and OPEB items.



Adjusted Net Income

March 31, 2019 (\$ in thousands) 2020 Net income attributable to Albemarle Corporation 107,204 \$ 133,569 Add back: Non-operating pension and OPEB items (net of tax) (2,311) (569) Non-recurring and other unusual items (net of tax) 1,493 (2,012)Adjusted net income attributable to Albemarle Corporation 106,386 \$ 130,988 \$ Adjusted diluted earnings per share \$ 1.00 \$ 1.23 Weighted-average common shares outstanding - diluted 106.512 106.356

Three Months Ended



See above for a reconciliation of adjusted net income, the non-GAAP financial measures, to Net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP.

EBITDA and Adjusted EBITDA

	Three Months Ended		Ended	
	March 31,			,
(\$ in thousands)	2020 2019		2019	
Net income attributable to Albemarle Corporation	\$	107,204	\$	133,569
Add back:				
Interest and financing expenses		16,885		12,586
Income tax expense		18,442		37,514
Depreciation and amortization		53,694		49,283
EBITDA		196,225		232,952
Non-operating pension and OPEB items		(2,908)		(583)
Non-recurring and other unusual items		3,048		(6,502)
Adjusted EBITDA		196,365		225,867
Net sales	\$	738,845	\$	832,064
EBITDA margin		26.6%		28.0%
Adjusted EBITDA margin		26.6%		27.1%



Adjusted EBITDA - by Segment (three months ended March 31)

(\$ in thousands)	Lithium	Brom	nine Specialties	Reportabl Catalysts Segments To		Reportable egments Total	All Other			Corporate	Cor	solidated Total
Three months ended March 31, 2020					_				_			
Net income (loss) attributable to Albemarle Corporation	\$ 53,240	\$	71,665	\$ 34,892	\$	159,797	\$	20,846	\$	(73,439)	\$	107,204
Depreciation and amortization	25,397		11,597	12,578		49,572		1,978		2,144		53,694
Non-recurring and other unusual items	_		_	_		—		_		3,048		3,048
Interest and financing expenses	_		_	_		_		_		16,885		16,885
Income tax expense	_		_	_		_		_		18,442		18,442
Non-operating pension and OPEB items	_		_	_		_		_		(2,908)		(2,908)
Adjusted EBITDA	\$ 78,637	\$	83,262	\$ 47,470	\$	209,369	\$	22,824	\$	(35,828)	\$	196,365
Three months ended March 31, 2019												
Net income (loss) attributable to Albemarle Corporation	\$ 93,169	\$	67,480	\$ 47,859	\$	208,508	\$	5,206	\$	(80,145)	\$	133,569
Depreciation and amortization	22,092		11,117	12,212		45,421		2,037		1,825		49,283
Non-recurring and other unusual items	355		_	_		355		_		(6,857)		(6,502)
Interest and financing expenses	_		_	_		—		_		12,586		12,586
Income tax expense	_		_	_		—		_		37,514		37,514
Non-operating pension and OPEB items	_		_	_		—		_		(583)		(583)
Adjusted EBITDA	\$ 115,616	\$	78,597	\$ 60,071	\$	254,284	\$	7,243	\$	(35,660)	\$	225,867

ALBEMARLE*

Adjusted EBITDA - Margin by Segment (three months ended March 31)

(\$ in thousands)	Lithium	Bromine Specialties	Catalysts		Reportable Segments Total								All Other	Con	solidated Total
Three months ended March 31, 2020															
Net sales	\$ 236,818	\$ 231,592	\$ 207,207	\$	675,617	\$	63,228	\$	738,845						
Net income (loss) attributable to Albemarle Corporation	22.5%	30.9%	16.8%		23.7%		33.0%		14.5%						
Depreciation and amortization	10.7%	5.0%	6.1%		7.3%		3.1%		7.3%						
Non-recurring and other unusual items	—%	—%	—%		—%		—%		0.4%						
Interest and financing expenses	—%	—%	—%		—%		—%		2.3%						
Income tax expense	—%	—%	—%		—%		—%		2.5%						
Non-operating pension and OPEB items	—%	—%	—%		—%		—%		(0.4)%						
Adjusted EBITDA Margin	 33.2%	 36.0%	 22.9%		31.0%		36.1%		26.6%						
Three months ended March 31, 2019															
Net sales	\$ 291,886	\$ 249,052	\$ 251,648	\$	792,586	\$	39,478	\$	832,064						
Net income (loss) attributable to Albemarle Corporation	31.9%	27.1%	19.0%		26.3%		13.2%		16.1%						
Depreciation and amortization	7.6%	4.5%	4.9%		5.7%		5.2%		5.9%						
Non-recurring and other unusual items	0.1%	—%	—%		—%		—%		(0.8)%						
Interest and financing expenses	—%	—%	—%		—%		—%		1.5%						
Income tax expense	—%	—%	—%		—%		—%		4.5%						
Non-operating pension and OPEB items	—%	—%	—%		—%		—%		(0.1)%						



See above for adjusted EBITDA margin, a non-GAAP financial measure defined as adjusted EBITDA divided by net sales. See previous slide for the related reconciliation of adjusted EBITDA on a segment basis, the non-GAAP financial measure, to Net income attributable to Albemarle Corporation ("earnings"), the most directly comparable financial measure calculated and reporting in accordance with GAAP.

Adjusted EBITDA - Continuing Operations (twelve months ended)

	Twelve Months Ended										
(\$ in thousands)		/lar 31, 2019	Jun 30, 2019		Sep 30, 2019			Dec 31, 2019		Mar 31, 2020	
Net income attributable to Albemarle Corporation	\$	695,371	\$	547,108	\$	572,433	\$	533,228	\$	506,863	
Depreciation and amortization		199,651		202,125		206,905		213,484		217,895	
Non-recurring and other unusual items (excluding items associated with interest expense)		(131,540)		67,457		64,683		117,243		126,793	
Interest and financing expenses		51,453		49,746		47,866		57,695		61,994	
Income tax expense		161,979		112,288		104,462		88,161		69,089	
Non-operating pension and OPEB items		6,899		8,427		10,071		26,970		24,645	
Adjusted EBITDA	\$	983,813	\$	987,151	\$	1,006,420	\$	1,036,781	\$	1,007,279	
Net Sales	\$	3,385,385	\$	3,416,563	\$	3,518,562	\$	3,589,427	\$	3,496,208	
Adjusted EBITDA Margin		29%		29%		29%		29%		29%	



Adjusted EBITDA - by Segment (twelve months ended)

	Twelve Months Ended											
(\$ in thousands)		Mar 31, 2019		Jun 30, 2019		Sep 30, 2019		Dec 31, 2019		Mar 31, 2020		
Lithium												
Net income attributable to Albemarle Corporation	\$	413,047	\$	413,058	\$	424,881	\$	341,766	\$	301,837		
Depreciation and amortization		93,220		93,260		95,102		99,424		102,729		
Non-recurring and other unusual items		9,108		9,219		9,384		83,744		83,389		
Adjusted EBITDA		515,375		515,537		529,367		524,934		487,955		
Net Sales		1,222,025		1,229,220		1,288,678		1,358,170		1,303,102		
Adjusted EBITDA Margin			42%	42% 41%			39%		37%			
Bromine Specialties												
Net income attributable to Albemarle Corporation	\$	254,453	\$	264,396	\$	271,653	\$	279,945	\$	284,130		
Depreciation and amortization		42,291		44,313		46,143		47,611		48,091		
Non-recurring and other unusual items		_		_		1,142		901		901		
Adjusted EBITDA		296,744		308,709		318,938	_	328,457		333,122		
Net Sales		941,293		976,212		999,863		1,004,216		986,756		
Adjusted EBITDA Margin		32%		32%						34%		
Catalysts												
Net income attributable to Albemarle Corporation	\$	437,803	\$	211,040	\$	214,894	\$	219,686	\$	206,719		
Depreciation and amortization		49,173		49,004		49,492		50,144		50,510		
Non-recurring and other unusual items		(210,428)		8,277		8,277		794		794		
Adjusted EBITDA		276,548		268,321		272,663		270,624		258,023		
Net Sales		1,092,485		1,073,820		1,084,027		1,061,817		1,017,376		
Adjusted EBITDA Margin		25%		25%		25%		25%		25%		

See above for a reconciliation of adjusted EBITDA on a segment basis, the non-GAAP financial measures, to Net income attributable to Albemarle Corporation ("earnings"), the most directly comparable financial measure calculated and reporting in accordance with GAAP.



Adjusted EBITDA supplemental¹

(\$ in thousands)	Tw	elve Months Ended	Three Months Ended			s Ended				
	Mar 31, 2020		_	Mar 31, 2020		Dec 31, 2019		Sep 30, 2019		Jun 30, 2019
Adjusted EBITDA	\$	1,007,279	\$	196,365	\$	294,663	\$	254,351	\$	261,900
Net income attributable to noncontrolling interests		69,603		16,431		15,852		16,548		20,772
Equity in net income of unconsolidated investments (net of tax)		(120,991)		(26,604)		(22,841)		(33,236)		(38,310)
Dividends received from unconsolidated investments		46,284		_		8,764		2,691		34,829
Consolidated EBITDA	\$	1,002,175	\$	186,192	\$	296,438	\$	240,354	\$	279,191
Total Long Term Debt (as reported)	\$	3,140,840								
Off balance sheet obligations and other		83,400								
Consolidated Funded Debt	\$	3,224,240								
Less Cash		553,228								
Consolidated Funded Net Debt	\$	2,671,012								
Consolidated Funded Debt to Consolidated EBITDA Ratio		3.2								
Consolidated Funded Net Debt to Consolidated EBITDA Ratio		2.7								

¹ This supplemental is for net-debt-to-adjusted EBITDA ratio based on the bank covenant definition.



Diluted EPS

Three Months Ended

		March 31,				
			2019			
Diluted earnings per share attributable to Albemarle Corporation	\$	1.01	\$	1.26		
Add back:						
Non-operating pension and OPEB items (net of tax)		(0.02)		(0.01)		
Non-recurring and other unusual items (net of tax)						
Restructuring and other		0.01		_		
Acquisition and integration related costs		0.02		0.04		
Gain on sale of property		_		(0.08)		
Other		(0.01)		(0.01)		
Discrete tax items		(0.01)		0.03		
Total non-recurring and other unusual items		0.01		(0.02)		
Adjusted diluted earnings per share ¹	\$	1.00	\$	1.23		

Effective Tax Rate

(\$ in thousands)	and equit	Income before income taxes and equity in net income of unconsolidated investments			Effective income tax rate
Three months ended March 31, 2020					
As reported	\$	115,473	\$	18,442	16.0%
Non-recurring, other unusual and non-operating pension and OPEB items		461		958	
As adjusted	\$	115,934	\$	19,400	16.7%
Three months ended March 31, 2019					
As reported	\$	153,859	\$	37,514	24.4%
Non-recurring, other unusual and non-operating pension and OPEB items		(7,085)		(4,504)	
As adjusted	\$	146,774	\$	33,010	22.5%

.

. . .



Equity Income and Noncontrolling Interest

	I nree Months Ended March 31,											
		2	020	2019								
(\$ in thousands)	Equ	uity Income	•	Noncontrolling Interest		Equity Income		Noncontrolling Interest				
Lithium	\$	33,507	\$	_	\$	29,370	\$	_				
Bromine Specialties		_		(16,433)		_		(17,939)				
Catalysts		5,662		_		5,811		_				
Corporate		(12,565)		2		_		(18)				
Total Company	\$	26,604	\$	(16,431)	\$	35,181	\$	(17,957)				

Three Months Ended March 31

Note: Corporate equity income relates to foreign exchange gains or losses of our Windfield Holdings joint venture.





www.albemarle.com

